Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00280-016-3009-7 http://scihub22266oqcxt.onion/10.1007/s00280-016-3009-7 C5978416!5978416 !27014780     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27014780 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Chemother+Pharmacol 2016 ; 77 (5 ): 973-7 Nephropedia Template TP {{tp|p=27014780 |t=2016. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers |pdf=|usr=}}{{27014780 }} gab.com Text Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers JO: Cancer Chemother Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=27014780 #FOAvip PURPOSE: Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with advanced/refractory cancers. METHODS: Temsirolimus, 25 mg weekly, was combined with an escalating daily dose of metformin (level 1: 500; level 2: 1000; level 3: 1500; level 4: 2000 mg) by utilizing a standard 3 + 3 trial design. Treatment was administered in 28-day cycles following initial 2-week metformin titration during the first cycle. RESULTS: Twenty-one patients (median age, 56 years) with sarcoma (n = 8), colorectal (n = 3), endometrial (n = 4), uterine carcinosarcoma (n = 2), ovarian (n = 2), and other (n = 2) cancers were enrolled. Patients had received median of four prior systemic treatments. Two dose-limiting toxicities were observed (grade 3 mucositis, grade 3 renal failure); both patients continued treatment after dose modification. Fifty-six percent patients had stable disease as best response; clinical benefit rate was 22 %. Patients continued treatment for median of 11 weeks. CONCLUSIONS: Combination temsirolimus/metformin was well tolerated with modestly promising effectiveness among this heavily pretreated patient cohort. We recommend a dose of temsirolimus 25 mg weekly and metformin 2000 mg daily for phase II study. Twit Text FOAVip Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers ????Cancer Chemother Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=27014780 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27014780 #FOAvip English Wikipedia <ref>{{Cite pmid|27014780 }}</ref> Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers #MMPMID27014780 Khawaja MR ; Nick AM ; Madhusudanannair V ; Fu S ; Hong D ; McQuinn LM ; Ng CS ; Piha-Paul SA ; Janku F ; Subbiah V ; Tsimberidou A ; Karp D ; Meric-Bernstam F ; Lu KH ; Naing A Cancer Chemother Pharmacol 2016[May]; 77 (5 ): 973-7 PMID27014780 show ga PURPOSE: Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with advanced/refractory cancers. METHODS: Temsirolimus, 25 mg weekly, was combined with an escalating daily dose of metformin (level 1: 500; level 2: 1000; level 3: 1500; level 4: 2000 mg) by utilizing a standard 3 + 3 trial design. Treatment was administered in 28-day cycles following initial 2-week metformin titration during the first cycle. RESULTS: Twenty-one patients (median age, 56 years) with sarcoma (n = 8), colorectal (n = 3), endometrial (n = 4), uterine carcinosarcoma (n = 2), ovarian (n = 2), and other (n = 2) cancers were enrolled. Patients had received median of four prior systemic treatments. Two dose-limiting toxicities were observed (grade 3 mucositis, grade 3 renal failure); both patients continued treatment after dose modification. Fifty-six percent patients had stable disease as best response; clinical benefit rate was 22 %. Patients continued treatment for median of 11 weeks. CONCLUSIONS: Combination temsirolimus/metformin was well tolerated with modestly promising effectiveness among this heavily pretreated patient cohort. We recommend a dose of temsirolimus 25 mg weekly and metformin 2000 mg daily for phase II study. |Adolescent [MESH] |Adult [MESH] |Aged [MESH] |Aged, 80 and over [MESH] |Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/therapeutic use [MESH] |Dose-Response Relationship, Drug [MESH] |Drug Administration Schedule [MESH] |Female [MESH] |Humans [MESH] |Male [MESH] |Maximum Tolerated Dose [MESH] |Metformin/*administration & dosage/adverse effects/therapeutic use [MESH] |Middle Aged [MESH] |Neoplasms/*drug therapy [MESH] |Response Evaluation Criteria in Solid Tumors [MESH] |Sirolimus/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use [MESH] |TOR Serine-Threonine Kinases/antagonists & inhibitors [MESH]Phase I dose escalation study of temsirolimus in combination with metf(epmc).pdf DeepDyve Pubget Overpricing